Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBCBS NC Rituximab Coverage Update: Prior Auth | Op…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Rituximab for the Treatment of Rheumatoid Arthritis - Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior-authorization requirements for rituximab (Rituxan and biosimilars) for adults with moderately to severely active rheumatoid arthritis who have inadequate response to prior therapies; applies to Blue Cross Blue Shield of North Carolina members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyRituximab for the Treatment of Rheumatoid Arthritis - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial operational updates to step therapy, documentation, and prescriber/screening requirements
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document trials of preferred rituximab biosimilars (Riabni, Ruxience, Truxima) or document intolerance/contraindication, plus hepatitis B screening and specialist prescriber or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    Added Riabni to the list of preferred rituximab biosimilars required to be tried before non-preferred products and explicitly included Rituxan as non-preferred.

    Clarified that inadequate response to methotrexate requires maximally tolerated dosing (example: titrated to 25 mg weekly) for at least 3 months.

    Changed biologic trial requirement language to require at least one biologic immunomodulator (FDA labeled or compendia supported) tried for at least 3 months, with allowances for intolerance/hypersensitivity/contraindication.

    Added requirement that prescriber be a specialist or consult with a specialist and that hepatitis B screening (HBsAg and antiHBc) be performed prior to therapy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=18Minimum age for RA indication
    365dDuration of approval
    600Maximum units per approval
    J9312, Q5123, Q5119, Q5115HCPCS codes
    HBsAg+antiHBcRequired HBV tests